Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Autor: Abrisqueta, Pau, López-Jiménez, Javier, Osorio, Santiago, Angel Hernandez Rivas, Jose, de la Cruz, Fatima, Magnano, Laura, María Arguiñano, José, González, Marcos, de la Serna, Javier, Szoke, Anita, Neumayr, Lynne D., Diels, Joris, Schioppa, Claudio A., Rubio Azpeitia, Eva, Domínguez-Lubillo, Teresa
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S184-S184
Databáze: ScienceDirect
Externí odkaz: